Diabetes Research and Clinical Practice
Volume 68, Issue 2 , Pages 167-175 , May 2005

Effect on glycemic control of the addition of 2.5mg glipizide GITS to metformin in patients with T2DM

  • M. Feinglos

      Affiliations

    • Duke University Medical Center, Division of Endocrinology, Box 3921, Durham, NC 27710, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1 919 684 4005; fax: +1 919 681 8477.
    • ,
  • G. Dailey

      Affiliations

    • Scripps Clinic and Research Foundation, La Jolla, CA, USA
    • ,
  • W. Cefalu

      Affiliations

    • Pennington Biomedical Research Center, Louisiana State University, Baton Rouge, LA, USA
    • ,
  • K. Osei

      Affiliations

    • Division of Endocrinology, Diabetes and Metabolism, Ohio State University Medical Center, Columbus, OH, USA
    • ,
  • J. Tayek

      Affiliations

    • Harbor-UCLA Medical Center, Torrance, CA, USA
    • ,
  • W. Canovatchel

      Affiliations

    • Pfizer Inc., New York, NY, USA
    • ,
  • R. Chaiken

      Affiliations

    • Pfizer Inc., New York, NY, USA
    • ,
  • I. Kourides

      Affiliations

    • Pfizer Inc., New York, NY, USA

Received 20 August 2004 ,Accepted 9 September 2004.

References 

  1. Scheen AJ. Drugs. Drug treatment of non-insulin-dependent diabetes mellitus in the 1990s. Achievements and future developments. 1997;54:355–368
  2. Scheen AJ, Lefebvre PJ. Oral antidiabetic agents. A guide to selection. Drugs. 1998;55:225–236
  3. Lee A, Morley JE. Metformin decreases food consumption and induces weight loss in subjects with obesity with type II non-insulin-dependent diabetes. Obes. Res. 1998;6:47–53
  4. DeFronzo RA, Goodman AM The Multicenter Metformin Study Group. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. N. Engl. J. Med. 1995;333:541–549
  5. Werner AL, Travaglini MT. A review of rosiglitazone in type 2 diabetes mellitus. Pharmacotherapy. 2001;21:1082–1099
  6. UK Prospective Diabetes Study Group, Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33), Lancet 352 (1998) 837–853.
  7. Charpentier G. Oral combination therapy for type 2 diabetes. Diabetes Metab. Res. Rev. 2002;18:S70–S76
  8. Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). JAMA. 1999;281:2005–2012
  9. Cefalu WT, Schneider DJ, Carlson HE, et al. Effect of combination glipizide GITS/metformin on fibrinolytic and metabolic parameters in poorly controlled type 2 diabetic subjects. Diabetes Care. 2002;25:2123–2128
  10. Hermann LS, Schersten B, Blitzen PO, Kjellstrom T, Lindegarde F, Melander A. Therapeutic comparison of metformin and sulfonylurea, alone and in various combinations. A double-blind controlled study. Diabetes Care. 1994;17:1100–1109
  11. Charpentier G, Fleury F, Kabir M, Vaur L, Halimi S. Improved glycemic control by addition of glimepiride to metformin monotherapy in type 2 diabetic patients. Diabet. Med. 2001;18:828–834
  12. Bayraktar M, Van Thiel DH, Adalar N. A comparison of acarbose versus metformin as an adjuvant therapy in sulfonylurea-treated NIDDM patients. Diabetes Care. 1996;19:252–254
  13. Halimi S, Le Berre MA, Grange V. Efficacy and safety of acarbose add-on therapy in the treatment of overweight patients with type 2 diabetes inadequately controlled with metformin: a double-blind, placebo-controlled study. Diabetes Res. Clin. Pract. 2000;50:49–56
  14. Phillips P, Karrasch J, Scott R, Wilson D, Moses R. Acarbose improves glycemic control in overweight type 2 diabetic patients insufficiently treated with metformin. Diabetes Care. 2003;26:269–273
  15. Rosenstock J, Brown A, Fischer J, et al. Efficacy and safety of acarbose in metformin-treated patients with type 2 diabetes. Diabetes Care. 1998;21:2050–2055
  16. Willms B, Ruge D. Comparison of acarbose and metformin in patients with type 2 diabetes mellitus insufficiently controlled with diet and sulfonylureas: a randomized, placebo-controlled study. Diabet. Med. 1999;16:755–761
  17. Moses R, Slobodniuk R, Boyages S, et al. Effect of repaglinide addition to metformin monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care. 1999;22:119–124
  18. Fonseca V, Rosenstock J, Patwardhan R, Salzman A. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized, controlled trial. JAMA. 2000;283:1695–1702
  19. Einhorn D, Rendell M, Rosenzweig J, Egan JW, Mathisen AL, Schneider RL. Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. Clin. Ther. 2000;22:1395–1409
  20. Campbell IW, Howlett HCS. Worldwide experience of metformin as an effective glucose-lowering agent: a meta-analysis. Diabetes Metab. Rev. 1995;11(Suppl. 1):S57–S62
  21. Dunn CJ, Peters DH, Metformin . A review of its pharmacological properties and therapeutic use in non-insulin-dependent diabetes mellitus. Drugs. 1995;49:721–749
  22. Simonson DC, Kourides IA, Feinglos M, Shamoon H, Fischette CT The Glipizide Gastrointestinal Therapeutic System Study Group. Efficacy, safety, and dose–response characteristics of glipizide gastrointestinal therapeutic system on glycemic control and insulin secretion in NIDDM. Results of two multicenter, randomized, placebo-controlled clinical trials. Diabetes Care. 1997;20:597–606
  23. Berelowitz M, Fischette C, Cefalu W, Schade DS, Sutfin T, Kourides IA. Comparative efficacy of a once-daily controlled-release formulation of glipizide and immediate-release glipizide in patients with NIDDM. Diabetes Care. 1994;17:1460–1464
  24. Blonde L, Guthrie RD, Tive L, Fischette C. Glipizide GITS is effective and safe in a wide range of NIDDM patients: results of a double-blind placebo-controlled efficacy and safety trial. Diabetologia. 1996;39(Suppl. 1):231;(abstract)
  25. Riddle MC, McDaniel PA, Tive LA. Glipizide-GITS does not increase the hypoglycemic effect of mild exercise during fasting in NIDDM. Diabetes Care. 1997;20:992–994
  26. Burge MR, Schmitz-Fiorentino K, Fischette C, Qualis CR, Schade DS. A prospective trial of risk factors for sulfonylurea-induced hypoglycemia in type 2 diabetes mellitus. JAMA. 1998;279:137–143
  27. UK Prospective, Diabetes Study Group, UK prospective diabetes study 16, Overview of 6 years therapy of type II diabetes: a progressive disease, Diabetes 44 (1995) 1249–1258.
  28. Chiasson J-L, Josse RG, Hunt JA, et al. The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus, A multicenter controlled clinical trial. Ann. Intern. Med. 1994;121:928–935
  29. American Diabetes Association, Standards of medical care for patients with diabetes mellitus, Diabetes Care 25 (2002) S13–S49.
  30. Testa MA, Simonson DC, Turner RR. Valuing quality of life and improvements in glycemic control in people with type 2 diabetes. Diabetes Care. 1998;21(Suppl. 3):C44–C52
  31. Cefalu WT, Bell-Farrow A, Wang ZQ, McBride D, Dalgleish D, Terry JG. Effect of glipizide GITS on insulin sensitivity, glycemic indices, and abdominal fat composition in NIDDM. Drug Dev. Res. 1998;44:1–7
  32. Blonde L, Guthrie RD, Tive L, Fischette C. Glipizide GITS therapy improved glycemic control without increasing body weight or adversely affecting plasma lipids in a large, double-blind, placebo-controlled efficacy and safety trial. Diabetes. 1997;46:158;(abstract)
  33. Feinglos M, Matusik H, Gibson E, Chaiken R. Long-term glipizide GITS (GXL) therapy does not cause weight gain. Diabetes. 2001;50:434;(abstract)

☆ Some of these data have been presented in abstract form at the ADA 2003 (M. Feinglos et al., Diabetes 52 (Suppl. 1) (2003) A118, 509-P).

PII: S0168-8227(04)00290-6

doi: 10.1016/j.diabres.2004.09.002

Diabetes Research and Clinical Practice
Volume 68, Issue 2 , Pages 167-175 , May 2005

Article Tools

* Image Usage & Resolution